Androgenetic alopecia (AGA), commonly known as male-pattern baldness affects 147 million people worldwide, including 6.8 million people in U.S. alone. The potential market size is anticipated to reach USD 4.8 billion by 2026 at a CAGR of 8.3%.
Using BioHubble, we found a few interesting startups working on male pattern baldness.
Stemson Therapeutics (San Diego, CA, USA) is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells (iPSC). It secured a significant investment in its seed financing round by Allergan, a leading global pharmaceutical company in June 2019.
SamuMed's (San Diego, CA, USA) technology platform focus is on the ability to modulate the Wnt pathway in select tissues with small molecules; the platform is not a "stem cell therapy." It has a Phase III candidate SM04554 for Androgenetic alopecia (AGA).
Concert Pharmaceuticals (Lexington, MA, USA) is developing CTP-543, an oral inhibitor of Janus kinases JAK1 and JAK2, as a potential treatment for alopecia areata.
Follica (Boston, MA ) is a biotechnology company developing a platform technology for hair loss based on breakthrough research in regenerative biology. The technology is based on a proprietary approach intended to create an "embryonic window" in adult skin, allowing new follicles and new hair to form from epithelial stem cells.
HairClone (Manchester, UK) is focusing on a clinical therapy for the treatment of androgenic alopecia in men and women. HairClone™ intends to develop a unique Business Strategy involving clinicians, scientists and patients co-funding and co-developing a private patient treatment using a combination of scientific and medical innovation.
Follicum (Lund, Sweden) has developed the first Artificial Intelligence software analysis tool to non-invasively evaluate oocytes (eggs), creating the only objective classification and prediction tool for an oocyte.
Cassiopea SpA (Lainate, Italy) is a clinical-stage specialty pharmaceutical company which is developing Clascoterone (Breezula®) solution 7.5%, an Androgen receptor inhibitor currently in Phase II trial in men with androgenic alopecia (AGA).
Do you have FOMO - Fear of Missing Out? Stay in the know with BioHubble.
Reserve your spot for early access.